Refine by
Radiation Therapy Technology Articles & Analysis
9 news found
BNCT has the potential to deliver highly effective, cell-localized radiation therapy to treat tumors with minimal impact on the patient's quality of life compared to other available treatment options, such as radiation, chemotherapy or biological treatment modalities. ...
The patient, suffering from liver cancer (hepatocarcinoma), was treated with BAT-90, a technology involving the delivery of Yttrium-90-labelled microspheres through a proprietary device straight into the tumour, where they are retained by a fast-curing, biocompatible glue. Two months after injection, clinical results confirmed that BetaGlue Technologies' ...
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis ...
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced its intent to file a New Drug Application (NDA) for avasopasem manganese (avasopasem) for the treatment of radiotherapy-induced severe oral mucositis ...
BNCT is a targeted radiation cancer therapy in which neutron beams destroy only boron compound-bearing tumors without destroying neighboring normal tissue. BNCT has the potential to deliver highly effective and cell-localized radiation therapy to treat tumors with minimal impact on the patient’s quality of life compared to ...
No Grade 4 or 5 esophagitis in patients treated with avasopasem Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced topline results from the six-week, Phase 2a, open-label, single-arm AESOP trial of ...
ATHENS, Greece, November 24, 2021 Following our successful cooperation since 2018, we are excited to announce that RTsafe and Medical Physics Limited expand their cooperation by entering into a partnership agreement under which Medical Physics Limited will be the agent of RTsafe’s innovative solutions for quality assurance in radiotherapy in the United Kingdom. Moreover, our partnership ...
ByRTsafe
RTsafe, a medical technology company focused on improving the safety and accuracy of radiotherapy for cancer and other medical conditions, today announced that Biomedic Medical Group will be the exclusive distributor of RTsafe’s products in China. We are delighted to announce this new collaboration and looking forward to provide our products to the Chinese radiotherapy professionals. ...
ByRTsafe
Edinburgh Molecular Imaging Ltd, a company developing theragnostic agents targeting cancer, today announces the closing of a £3.1 million financing, which will be used to advance new molecular targeted systemic radiotherapy agents, EMT-100 and EMT-101 to be ready for clinic development. Current investors and one new investor supported the round. EMT-100 and EMT-101 have been developed as ...